- Open Access
Microrna-124 targets flotillin-1 to regulate proliferation and migration in breast cancer
- Laisheng Li†1,
- Jinmei Luo†2,
- Bo Wang†1,
- Dong Wang1,
- Xinhua Xie3,
- Linjing Yuan4,
- Jiaoli Guo3,
- Shaoyan Xi5,
- Jie Gao3,
- Xiaoti Lin3,
- Yanan Kong3,
- Xiangdong Xu6,
- Hailing Tang3,
- Xiaoming Xie3 and
- Min Liu1Email author
© Li et al.; licensee BioMed Central Ltd. 2013
- Received: 12 August 2013
- Accepted: 11 December 2013
- Published: 13 December 2013
MicroRNAs (miRNAs) have been documented as playing important roles in cancer development. In this study, we investigated the role of miR-124 in breast cancer and clarified the regulation of flotillin-1 (FLOT1) by miR-124.
The expression levels of miR-124 were examined in breast cancer cell lines and patient specimens using quantitative reverse transcription-PCR. The clinicopathological significance of the resultant data was later analyzed. Next, we explored the function of miR-124 to determine its potential roles on cancer cell growth and migration in vitro. A luciferase reporter assay was conducted to confirm the target gene of miR-124, and the results were validated in cell lines and patient specimens.
We found that miR-124 expression was significantly downregulated in breast cancer cell lines and patient specimen compared with normal cell lines and paired adjacent normal tissues (P < 0.0001), respectively. MiR-124 was also associated with tumor node metastasis (TNM) stage (P = 0.0007) and lymph node metastasis (P = 0.0004). In breast cancer cell lines, the ectopic expression of miR-124 inhibited cell growth and migration in vitro. Moreover, we identified the FLOT1 gene as a novel direct target of miR-124, and miR-124 ectopic expression significantly inhibited FLOT1. Luciferase assays confirmed that miR-124 could directly bind to the 3′ untranslated region of FLOT1 and suppress translation. Moreover, FLOT1 was widely upregulated, and inversely correlated with miR-124 in breast cancer tissues. Consistent with the effect of miR-124, the knockdown of FLOT1 significantly inhibited breast cancer cell growth and migration. We also observed that the rescue expression of FLOT1 partially restored the effects of miR-124.
Our study demonstrated that miR-124 might be a tumor suppressor in breast cancer via the regulation of FLOT1. This microRNA could serve as a potential diagnostic marker and therapeutic target for breast cancer.
- Breast cancer
Breast cancer is the leading cause of cancer death in females worldwide. Due to the advances in diagnosis and appropriately systemic therapy, including surgery, radiation and chemotherapy, the prognosis of breast cancer is encouraging. However, similar to many other solid tumors, distant metastases account for more than 90% of breast cancer-related death . Because the underlying mechanisms of breast cancer metastasis consist of multiple sequential steps that are not completely understood to date, further investigation of this mechanism is urgently needed.
MicroRNAs (miRNAs) are endogenous noncoding small RNAs that contribute to the regulation of their cognate target genes by usually imperfect base-pairing to the 3′ untranslated region (UTR) of a target mRNA, which results in either mRNA degradation or translation inhibition . In fact, miRNAs are implicated in the regulation of various cellular processes, including proliferation, differentiation, cell death and cell mobility . Furthermore, miRNA profiles also indicate that miRNAs can function either as oncogenes or tumor suppressors in tumor progression [4, 5]. Therefore, miRNA expression profiles constitute progress in cancer diagnosis, classification, clinical prognostic information and therapy [6–10].
Previous studies of miRNA profiles demonstrated several deregulated miRNAs in breast cancer, including miR-124[11–13]. MiR-124, a brain-enriched miRNA, was first found to be involved in stem cell regulation and neurodevelopment [14, 15]. Previous research confirmed that miR-124 is epigenetically silenced in various types of cancer and regulated cancer cell biological behaviors by targeting several important genes, such as sphingosine kinase 1 (SPHK1), rho-kinase2 (ROCK2), enhancer of zeste homologue 2 (EZH2), RAC1, the androgen receptor and CD151 [16–20]. Recent studies further revealed that miR-124 plays important roles in the regulation of growth, metastasis and epithelial-mesenchymal transition (EMT) in breast cancer [16, 21, 22]. These studies suggested that miR-124 can serve as a potential tumor suppressor. Our study showed that miR-124 was downregulated in breast cancer, and a bioinformatic analysis predicted flotillin-1 (FLOT1) to be a potential target of miR-124.
FLOT1 is overexpressed in several types of cancer, including breast cancer [23–26]. FLOT1 was originally identified as a marker of lipids, which is important for non-caveolar raft formation and associated with the development and progression of cancer. In breast cancer, the FLOT1 expression level correlated with clinical staging and prognosis, and its silencing inhibited the proliferation and tumorigenicity of breast cancer cells in vitro and vivo. MicroRNAs can regulate the expression levels of FLOT1 , a process that was intensively studied by our group. Our findings, consistent with other groups, indicated that the role of miR-124 in the growth and metastasis inhibition was accomplished by the regulation of FLOT1 in breast cancer.
In this study, we aimed to investigate the role of miR-124 in breast cancer. We found that downregulation of miR-124 in breast cancer tissues compared with the corresponding normal tissues, and inversely associated with TNM stage and lymph node metastasis in breast cancer. In addition, synthetic miR-124 mimics inhibited the growth and migration of breast cancer cells in vitro. Furthermore, we validated FLOT1, which was overexpressed in breast cancer and predicted as the target of miR-124, by 3′-UTR luciferase assays and western blot analysis. Finally, knockdown of FLOT1 consistent with the effects of miR-124 in breast cancer, and rescue expression of FLOT1 could partially restore these miR-124 effects. Our study demonstrated that miR-124 acts as a tumor suppressor by directly targeting FLOT1 in breast cancer, which suggested that miR-124 has potential diagnostic and therapeutic value for breast cancer treatment.
MiR-124 was downregulated in breast cancer cell lines and clinical specimens and inversely associated with advanced clinical stage and lymph node metastasis
The relationship between miR-124 expression and clinicopathological parameters in breast cancer
Number of cases
Median expression of miR-124
0.4252 ± 0.0403
0.3140 ± 0.0338
Tumor size (cm)
0.4107 ± 0.0573
0.3481 ± 0.0287
I + II
0.4128 ± 0.0307
III + IV
0.1951 ± 0.0231
Lymph node metastasis
0.4550 ± 0.0407
0.2720 ± 0.0265
0.3575 ± 0.0495
0.3732 ± 0.0320
0.3426 ± 0.0395
0.3850 ± 0.0361
0.3548 ± 0.0326
0.3906 ± 0.0469
Ectopic expression of miR-124 inhibited the proliferation, migration and invasion of breast cancer cells
After confirming the cell proliferation and growth inhibition ability of miR-124, we investigated the role of miR-124 in cell migration and invasion. Wound healing and Matrigel invasion assays demonstrated that the ectopic expression of miR-124 inhibited the cell migration and invasion of MDA-MB-231 and T47D cells compared with the mimic control (Figure 2E and F). The above results support the role of miR-124 in the inhibition of breast cancer proliferation, migration and invasion and suggest that miR-124 has a tumor suppressor function.
MiR-124 downregulated FLOT1 expression by directly targeting its 3′-UTR
We performed a luciferase reporter assay to determine whether FLOT1 is a direct target of miR-124 in breast cancer cells. The target region sequence of FLOT1 3′-UTR (wt 3′-UTR) or the mutant sequence (mut 3′-UTR) was cloned into a luciferase reporter vector (Figure 3B). These constructed reporter vectors were co-transfected with miR-124 mimics or miR-Ctrl into the MDA-MB-231 cell line. The data in Figure 3C show that miR-124 could downregulate the luciferase activity of the FLOT1 wt 3′-UTR construct (Figure 3C, lanes 3; P < 0.05), whereas the luciferase activity was not significantly attenuated in the target region of the mutated mut 3′-UTR construct (Figure 3C, lanes 4, 5 and 6). These data suggest that the regulation of miR-124 on FLOT1 depended on the specific seed region sequence. Moreover, miR-Ctrl did not significantly affect the luciferase activity of either the wt or mut 3′-UTR construct (Figure 3C, lanes 2 and 5).
We further analyzed the FLOT1 protein expression by using western blotting after transfecting MDA-MB-231 and T47D cells with miR-124 mimics. As shown in Figure 3D, the ectopic expression of miR-124 inhibited FLOT1 expression by approximately 60% to 70%. Therefore, we concluded that miR-124 inhibited FLOT1 expression by binding to the 3′-UTR sequences of FLOT1 in breast cancer.
Knockdown of FLOT1 induced inhibition of breast cancer cells proliferation and invasion
To test whether FLOT1 is the direct functional mediator of the miR-124 induced inhibition of breast cancer cell proliferation and migration, we co-transfected miR-124 mimics along with wt/mut 3′-UTR-FLOT1 plasmid which FLOT1 cDNA contained wild type or mutant 3′ UTR into breast cancer cells. MTT and Matrigel invasion assays showed that mut 3′-UTR-FLOT1 could partially abrogate the miR-124-mediated effects in breast cancer cells, to restore the proliferation and migration compared with the miR-Ctrl (Figure 4D and E; P < 0.05). Therefore, FLOT1 has an important role in the proliferation and invasion of breast cancer cells, which was regulated by miR-124.
MiR-124 and FLOT1 are inversely correlated in breast cancer tissues
Cancer is characterized by abnormal and uncontrolled cell proliferation, which is caused not only by the misregulation of several pivotal proteins but also by a systemic change in the miRNAs profile . MiRNAs are involved in the regulation of multiple biological processes, including development, cell proliferation, apoptosis, differentiation, disease survival and cell death [29, 30]. Considering the function of miRNAs, their deregulation expectedly contributes to substantial cell physiological and pathological processes and is ultimately involved in tumorigenesis and the tumor progression of many different human cancers. In this report, we showed that miR-124 was markedly downregulated in human breast cancer cell lines and clinical specimens compared with immortalized normal mammary epithelial cell lines and normal adjacent tissues, respectively. MiR-124 downregulation was significantly associated with advanced clinical stage and positive lymph node-metastasis in breast cancer patients. Furthermore, the ectopic expression of miR-124 inhibited breast cancer cell proliferation, migration and invasion. Moreover, FLOT1 was identified as a direct and functional target of miR-124 via binding to the 3′UTR of FLOT1. Our study suggested that miR-124 acts as a novel proliferation and metastasis suppressor in breast cancer, and downregulated miR-124 contributes to lymph node-metastasis and tumor progression in breast cancer patients.
Although miR-124 was identified long ago, its biological function has only recently been investigated. MiR-124 acts as a tumor suppressor, and its downregulation has been identified in various cancers [16, 18–22, 31–33], which suggests that miR-124 may play a vital role in tumorigenesis and tumor progression. Shi et al. showed that miR-124 was a potential tumor-suppressive miRNA and was downregulated in prostate cancer to result in proliferation inhibition of prostate cancer cells by targeting the androgen receptor . Wang et al. reported that miR-124 was epigenetically silenced in pancreatic cancer and inhibited cell proliferation and metastasis by regulating Rac1 . Zheng et al. showed that miR-124 levels were frequently reduced in hepatocellular carcinoma, and this expression level was significantly associated with the patients’ clinical stages and prognoses and regulated the invasion and migration of hepatocellular carcinoma through post-transcriptional regulation of ROCK2 and EZH2 . Lv et al., Liang et al. and Han et al. also reported that miR-124 can suppress breast cancer growth and metastasis [16, 21, 22]. Han et al. found that miR-124 is downregulated in breast cancer and the ectopic expression of miR-124 could suppress the invasion and metastatic ability, likely by directly targeting the CD151. CD151 regulates the ligand biding activity of integrin α3β1 and plays a role in Met-dependent signaling and TGF-β signaling, while c-met can regulate many cellular process, especially the proliferation and migration of cancer. These results suggest an important role for miR-124 in the proliferation and metastasis of different cancers. However, the miR-124 expression levels in clinical specimens and its exact mechanism in breast cancer has not been clearly elucidated. In this study, we demonstrated for the first time that miR-124 was frequently downregulated in breast cancer, and the average expression levels of miR-124 were significantly downregulated in breast cancer tissues compared with paired normal adjacent tissues. Interestingly, we found that lower levels of miR-124 are associated with advanced TNM stage (stage I + II vs. stage III + IV, P = 0.0007) and positive lymph node metastasis, suggesting that a low expression of miR-124 is associated with breast cancer progression. Recently, miR-124 was reported to be subject to epigenetic regulation in various tumors, including breast cancer [17, 31, 32, 34], which in turn may explain the downregulation of miR-124 in breast cancer. Taken together, these results suggest that miR-124 expression is frequently reduced in breast cancer, which may be responsible for the tumorigenesis and progression of breast cancer. However, the function of miR-124 in breast cancer is not fully understood.
The capability of cells to proliferate, migrate and invade is considered an important determinant in the process of tumorigenesis and progression. Many oncogenes and suppressor genes reportedly correlate with the course of cancer initiation and progression, but the molecular mechanisms are not fully understood. Recently, accumulating studies have reported that miRNAs play important roles in breast cancer tumorigenesis and progression [35–37]. Interestingly, a number of miRNAs are associated with the proliferation and migration of breast cancer, such as miR-26a, miR-34a, miR-137, and miR-210, which may provide new insights into the design of eradicating therapeutic strategies for breast cancer. Even miR-124 has been reported as a tumor suppressor miRNA in breast cancer. However, the mechanisms involved have not been fully elucidated. To determine the function of miR-124 in breast cancer, we tested the effect of miR-124 on MDA-MB-231 and T47D cell lines. Ours results indicate that miR-124 could suppress breast cancer cell proliferation, migration and invasion, which suggests its role as a tumor suppressor in breast cancer.
In the current study, we identified FLOT1 as a direct and functional target of miR-124. The protein encoded by the FLOT1 gene is an integral membrane protein that participates in vesicular trafficking, signal transduction and is important for lipid raft formation [25, 26, 42]. Accumulating evidence shows that the overexpression of FLOT1 in various cancers contributes to proliferative and invasive behavior as well as a worse prognosis [24–26]. The knockdown of FLOT1 reportedly suppressed the proliferation and tumorigenesis of breast cancer cells by enhancing the transcriptional activity of FOXO3a, inhibiting Akt activity, downregulating cyclin D1 and upregulating the cyclin-dependent kinase inhibitors p21Cip1 and p27Kip1. Xiong et al. also showed that Flotillin-1 could clearly activate the growth and metastasis of oral squamous carcinoma by transfecting cells with a Flotillin-1 expression vector or shRNA targeted Flotillin-1. This effect was mediated by the activation of the NF-κB signaling pathway, which enhanced the phosphorylation of p65 and IκBα . These studies showed that FLOT1 can regulate many cellular processes, particularly in cancer growth, proliferation, migration, metastasis and tumorigenesis. Consistent with the study above, we found that miR-124 could directly target and downregulate FLOT1, and high FLOT1 expression was associated with low miR-124 levels in breast cancer specimens. These findings provide new insight into the essential mechanisms of FLOT1 regulation in breast cancer. Additionally, miR-138 was also reported to regulate FLOT1 in esophageal squamous cell carcinoma. These findings suggest that the post-transcriptional regulation of FLOT1 by miRNAs is a vital mechanism underlying cancer proliferation and metastasis, and miR-124 may serve as potential treatment target for regulating FLOT1 to inhibit the growth and metastasis of breast cancer.
Our study demonstrates that miR-124 is downregulated and inversely associated with the lymph node metastasis in breast cancer. The ectopic expression of miR-124 inhibits cell proliferation and migration by downregulating FLOT1, which indicates the internal mechanism of tumor suppression of miR-124. Combined with the above mentioned studies, this work contributes to the understanding of the effect of miR-124 on tumor suppression. This study suggests that miR-124 downregulated may play an important role in tumor proliferation and migration and may be a novel diagnostic marker and potential therapeutic target in breast cancer.
Human breast cancer tissues
78 cases of human breast cancer and 40 corresponding normal breast tissues were collected at the time of surgical resection from the First Affiliated Hospital of Sun Yat-sen University and Sun Yat-sen University Cancer Center from (Guangzhou, China) 2009 to 2011. The samples were fixed in RNAlater (Ambion, Austin, TX, USA) immediately after surgical resection and stored at −80°C in a freezer until use. The breast cancer samples selected were based on a clear pathological diagnosis, and the clinical information for the samples is presented in Table 1. The tumor stage was defined according to the American Joint Committee on Cancer and tumor-lymph node-metastasis classification system . All patients provided consent for the use of their specimens in research, and this use was approved by the institute research ethics committee of the First Hospital of Sun Yat-sen University.
Inmmunohistochemistry (IHC) staining of formalin-fixed and paraffin-embedded tissue slides was performed and quantified as previously described . Briefly, 5 μm tissue slides were deparaffinized, rehydrated via a series of descending graded alcohols and subjected to antigen retrieval in 0.01 M citrate buffer (pH 6.0) at 90°C for 40 minutes. Following a blocking step, the slides were incubated with FLOT1 primary antibody (1:500; Sigma, Saint Louis, MO) and washed. Biotinylated secondary antibody was applied, and the immunocomplexes were visualized using an avidin-biotin complex immunoperoxidase system (Vector Laboratories, Burlingame, CA, USA) with 0.03% diaminobenzidine (DAB) as a chromagen and hematoxylin as the counterstain. We used phosphate-buffered saline (PBS) instead of the primary antibody as a negative control, and a composite slide containing formalin-fixed cell pellets of MDA-MB-231 and T47D as positive control to assess the quality of the IHC reaction. The slides were reviewed and scored independently based on both the percentage of positive stained tumor cells and overall stained intensity by two observers who were blinded to specimens’ clinical information. The following scoring rubric was used: scored 0, absent positive tumor cells; scored +, weak cell staining or <10% positive tumor cells; scored ++, moderate cell staining or 10-50% positive tumor cells; scored +++, strong cell staining or >50% positive tumor cells. Conflicts (approximately 5% of cases) were resolved by consensus.
The breast cancer cell lines MDA-MB-231, MDA-MB-361, MDA-MB-435, MDA-MB-468, MCF-7, HBL100, T47D, and 4 T1 and two immortalized normal mammary epithelial cell lines, MCF-10A and 184A1, were obtained from the American Type Culture Collection (Manassas, VA) and freshly recovered from liquid nitrogen (<3 months). The breast cancer cells were maintained according to the vendor’s instructions. Briefly, the breast cancer cells were maintained in Dulbecco’s modified Eagle’s medium (DMEM) or RPMI 1640 (Invitrogen, Beijing, China) supplemented with 10% fetal bovine serum (FBS, GIBCO, Cappinas, Brazil). MCF-10A cells were cultured in Keratinocyte-SFM (Invitrogen, CA, USA) supplemented with pre-qualified human recombinant epidermal growth factor 1–53 (EGF 1–53, Invitrogen, CA, USA) and bovine pituitary extract (BPE, Invitrogen, CA, USA). The 184A1 cells were cultured in Mammary Epithelium Basal Medium (MEBM, Clonetics, MD, USA). All cells were grown and maintained at 37°C in a 5% CO2 humidified incubator (Thermo Electron Corp, New Castle, DE).
The analysis of miR-124 predicted targets was determined using the algorithms of TargetScan 5.1 (http://www.targetscan.org/) and miRanda (http://www.microrna.org). According to these algorithms, we predicted that the FLOT1 gene might be a direct target of miR-124.
Transient transfection of miRNA and siRNA
The miR-124 mimics, a non-specific miRNA negative control (miR-Ctrl), small interfering RNA (siRNA) duplexes targeting human FLOT1 (FLOT1-siRNA) (sense strand, 5′-ACAGAGAGAUUACGAACUGAAdTdT-3′ and antisense strand, 5′-UUCAGUUCGUAAUCUCUCUGUdTdT-3′) and scrambled control siRNA (Ctrl-siRNA) (sense strand, 5′-UUCUCCGAACGUGUCACGUdTdT-3′ and antisense strand, 5′-ACGUGACACGUUCGGAGAAdTdT-3′) were synthesized and purified by RiboBio (Guangzhou, China). MiRNA mimics or siRNA duplexes were transfected at working concentrations of 50 nM using Lipofectamine 2000 reagent (Invitrogen, CA, USA), according to the manufacturer’s instruction.
RNA extraction and quantitative real-time PCR
The RNA extraction and quantitative real-time PCR procedure were carried out as previously reported . Briefly, total RNA was extracted using TRIzol® Reagent (Invitrogen, CA, USA). To quantitate the miR-124 expression, reverse transcription was performed with a specific stem-loop real-time PCR miRNA kit (RiboBio, Guangzhou, China). Quantitative real-time PCR (qPCR) was performed using the Platinum SYBR Green qPCR SuperMix-UDG system (Invitrogen, CA, USA) on an Applied Biosystems 7900HT real-time PCR system, and the data were collected and analyzed using ABI SDS version 2.3. All procedures were performed according to the manufacturer’s instructions. 5S rRNA was used as an internal control. All samples were normalized to internal controls, and the fold changes were calculated according to the relative quantification method (RQ = 2−ΔΔCT). The results are shown as fold changes of expression in cells or cancer tissues.
The primers of miR-124 and 5S rRNA used for stem-loop real-time PCR are listed as follows: miR-124 stem-loop RT, 5′-GTCGTATCCAGTGCAGGGTCCGAGGTATTCGCACTGGATACGACATCAAG-3′; miR-124 forward, 5′-GCGGCCGTGTTCACAGCGGACC-3′; miR-124 reverse, 5′-GTGCAGGGTCCGAGGT-3′; 5S rRNA stem-loop RT, 5′-GTCGTATCCAGTGCAGGGTCCGAGGTATTCGCACTGGATACGACCAGGCG-3′; 5S rRNA forward, 5′-CTGGTTAGTACTTGGACGGGAGAC-3′; 5S rRNA reverse, 5′-GTGCAGGGTCCGAGGT-3′.
The cell viability and proliferation of MDA-MB-231 and T47D with miRNA mimics or siRNA duplexes were determined by 3-(4, 5-dimethylthiazolyl-2-yl)-2-5 diphenyl tetrazolium bromide (MTT, Sigma, St. Louis, MO, USA) assay. The cells were plated in 96-well plates at 5 × 103 per well in a final volume of 100 μL and treated with miRNA mimics or siRNA duplexes. After incubation for 24, 48, 72 and 96 hours, the culture medium was replaced with 100 μL of fresh DMEM. Twenty-five microliters of MTT stock solution (5 g L-1 in phosphate-buffered saline) were added to each well to achieve a final concentration of 1 g L-1. The plates were incubated for another 4 hours, the culture medium was replaced with dimethyl sulfoxide (DMSO, Sigma, St. Louis, MO, USA), and the absorbance was measured at 570 nm by a SpectraMax M5 Microplate Reader (Molecular Deviced, Sunnyvale, CA, USA). The cell viability was normalized to that of cells cultured in the culture medium without miRNA mimics or siRNA duplexes. Three independent experiments (3 replicates in each) were performed.
Wound healing assay
To determine cell migration, MDA-MB-231 and T47D breast cancer cells transfected with miRNA mimics were seeded in six-well plates, incubated in their respective complete culture medium and grown to confluence overnight. Wounds were made by scraping with a sterilized 200 μL pipette tip, and the debris was rinsed with phosphate-buffered saline. Serial photographs were obtained at 0, 24 and 48 hours using a phase contrast microscope (Olympus IX81, Tokyo, Japan).
MiRNA-transfected cells were scratched using a standard 200 μL tip. The debris was removed by washing with serum-free medium. Serial photographs were obtained at different time points using a phase contrast microscope (Olympus IX81, Tokyo, Japan). Three independent experiments were carried out.
Transwell invasion assays
To determine cell invasion in vitro, Matrigel-coated invasion chambers (8 μm; BD Biosciences, CA, USA) were used according to the manufacturer’s protocol. Briefly, miRNA mimic- or siRNA duplex-transfected cells were harvested, re-suspended (1 × 105 cells per well) in 200 μL serum-free medium, and transferred to the upper chamber of the Matrigel-coated inserts; culture medium containing 10% FBS was placed in the bottom chamber. The cells were incubated for 24 hours at 37°C; the cells on the upper surface were then removed by peeling off the matrigel and swiping the top of the membrane with cotton swabs. The cells that had invaded the lower surface were fixed and stained with 0.5% crystal violet (Sigma, St Louis, MO, USA) for 30 min, counted under an inverted microscope (Olympus IX71, Tokyo, Japan), and the relative number of invading cells was calculated from five-field digital images taken randomly at 200× magnification. The data are the means ± SD of three independent experiments.
Cell cycle assays
To determine cell cycle distribution, the cells were plated in 6-well plates and transfected with miRNA mimics or siRNA duplexes. After transfection, the cells were collected by trypsinization, fixed in 70% ethanol, washed in PBS, re-suspended in 200 ml of PBS containing 1 mg/ml RNase, 0.05% Triton X-100 and 50 mg/ml propidium iodide (Sigma, St Louis, MO, USA), incubated for 30 min at 37°C in the dark, and analyzed immediately using a FACSCalibur instrument (Becton Dickinson, CA, USA). The data were analyzed using the CellQuest Pro software (BD Biosciences).
Colony formation assays
After transfecting with miRNA mimics or siRNA duplexes, the cells were seeded in 6-well plates at 5 × 102 per well and incubated for 2 weeks for the colony formation assay.
The cells were then washed twice with PBS, fixed with methanol/acetic acid (3:1, v/v), and stained with 0.5% crystal violet (Sigma, St Louis, MO, USA). The number of colonies was counted under the microscope (Olympus IX81, Tokyo, Japan).
The 3′-untranslated regions (3′-UTR) sequences of human FLOT1 containing the putative miR-124 binding sites were isolated from MDA-MB-231 cDNA using PCR amplification and cloned into the pGL3 vector (Promega, Madison, WI, USA), which was termed as wild-type 3′-UTR (wt 3′-UTR). The point mutations in the putative miR-124 binding seed regions were performed using the Quick-Change Site-Directed Mutagenesis kit (Stratagene, La Jolla, CA, USA) according to the manufacturer’s protocol. The resultant product served as the mutated 3′-UTR (mut 3′-UTR). Both the wild-type and mutant insert fragments sequences were confirmed by DNA sequencing.
For FLOT1 overexpression, the cDNA of FLOT1 containing the putative miR-124 binding sites was cloned into the multiple cloning site of the pcDNA3.1 vector (Invitrogen, Carlsbad, CA, USA), which was termed as wild-type 3′-UTR-FLOT1 (wt 3′-UTR-FLOT1). The mut 3′-UTR-FLOT1 was obtained as described above. In the rescue experiment, cells were cotransfected with 50 nM of miRNA mimics and 500 ng of plasmid in a six-well plate.
The cells were seeded in triplicate in 24-well plates one day before transfection for the luciferase assays. Wt or mut 3′-UTR vectors and the control vector pRL-TK (Promega, Madison, WI, USA) coding for Renilla lucifearse were co-transfected with miR-124 mimics or negative control into MDA-MB-231 cells using Lipofectamine 2000 reagent, as described previously. After 48 hours of transfection, the cells were harvested and lysed, and the luciferase activity was assayed using the Dual-Glo luciferase assays kit (Promega, Madison, WI, USA). The firefly luciferase values were normalized to Renilla, and the relative ratios of firefly to Renilla activity were reported. Three independent experiments were performed, and the data are presented as the mean ± SD.
Western blot analysis
Transfected MDA-MB-231 and T47D cells were cultured for 72 hours and then harvested on ice using RIPA lysis and extraction buffer (25 mM Tris–HCl pH 7.6, 150 mM NaCl, 1% NP-40, 1% sodium deoxycholate, 0.1% SDS, protease inhibitor cocktail (Pierce, Rockford, IL). The total cell extracts (20 μg protein) were separated using 10% SDS-polyacrylamide gels and electrophoretically transferred to polyvinylidene difluoride membranes (PVDF, Millipore, MA, USA). The membranes were incubated with mouse monoclonal antibody against human FLOT1 (Sigma, St Louis, MO, USA) followed by horseradish peroxidase (HRP)-conjugated goat-anti-mouse IgG (Abcam), and the bands were detected using the Supersignal West Pico ECL chemiluminescence kit (Pierce) and Kodak X-ray film (Eastman Kodak Co, NY, USA); an anti-tubulin antibody (Sigma, St Louis, MO, USA) was used as a protein loading control.
All experiments were performed at least three times, and all samples were tested in triplicate. The data are shown as the mean ± SEM unless otherwise noted; Student’s t-test was used for statistical analysis when only two groups were tested. A one-way analysis of variance was used to compare multiple groups. The difference in miR-124 and FLOT1 expressions between breast cancer specimens and normal adjacent tissues of human subjects was calculated by a two-tailed independent samples t-test. Spearman’s correlation analysis was used to determine the correlation between miR-124 and FLOT1 expressions. In all cases, a P < 0.05 was considered statistically significant.
This work was supported by grants from the Program of National Natural Science Foundation of China (No. 81272514), the China Postdoctoral Science Foundation (No. 2012 M520075) and the Specialized Research Fund for the Doctoral Program of Higher Education (20130171120069). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
- Chaffer CL, Weinberg RA: A perspective on cancer cell metastasis. Science. 2011, 331: 1559-1564. 10.1126/science.1203543View ArticlePubMedGoogle Scholar
- Bartel DP: MicroRNAs: genomics, biogenesis, mechanism, and function. Cell. 2004, 116: 281-297. 10.1016/S0092-8674(04)00045-5View ArticlePubMedGoogle Scholar
- Kasinski AL, Slack FJ: Epigenetics and genetics. MicroRNAs en route to the clinic: progress in validating and targeting microRNAs for cancer therapy. Nat Rev Cancer. 2011, 11: 849-864. 10.1038/nrc3166PubMed CentralView ArticlePubMedGoogle Scholar
- Chen CZ: MicroRNAs as oncogenes and tumor suppressors. N Engl J Med. 2005, 353: 1768-1771. 10.1056/NEJMp058190View ArticlePubMedGoogle Scholar
- Croce CM: Causes and consequences of microRNA dysregulation in cancer. Nat Rev Genet. 2009, 10: 704-714. 10.1038/nrg2634PubMed CentralView ArticlePubMedGoogle Scholar
- Garzon R, Marcucci G: Potential of microRNAs for cancer diagnostics, prognostication and therapy. Curr Opin Oncol. 2012, 24: 655-659. 10.1097/CCO.0b013e328358522cView ArticlePubMedGoogle Scholar
- Hoshino I, Matsubara H: MicroRNAs in cancer diagnosis and therapy: from bench to bedside. Surg Today. 2013, 43: 467-478. 10.1007/s00595-012-0392-5View ArticlePubMedGoogle Scholar
- Cho WC: MicroRNAs as therapeutic targets and their potential applications in cancer therapy. Expert Opin Ther Targets. 2012, 16: 747-759. 10.1517/14728222.2012.696102View ArticlePubMedGoogle Scholar
- Jones CI, Zabolotskaya MV, King AJ, Stewart HJS, Horne GA, Chevassut TJ, Newbury SF: Identification of circulating microRNAs as diagnostic biomarkers for use in multiple myeloma. Br J Cancer. 2012, 107: 1987-1996. 10.1038/bjc.2012.525PubMed CentralView ArticlePubMedGoogle Scholar
- Zhang X, Zeng J, Zhou M, Li B, Zhang Y, Huang T, Wang L, Jia J, Chen C: The tumor suppressive role of miRNA-370 by targeting FoxM1 in acute myeloid leukemia. Mol Cancer. 2012, 11: 56- 10.1186/1476-4598-11-56PubMed CentralView ArticlePubMedGoogle Scholar
- Volinia S, Galasso M, Sana ME, Wise TF, Palatini J, Huebner K, Croce CM: Breast cancer signatures for invasiveness and prognosis defined by deep sequencing of microRNA. Proc Natl Acad Sci USA. 2012, 109: 3024-3029. 10.1073/pnas.1200010109PubMed CentralView ArticlePubMedGoogle Scholar
- Sieuwerts AM, Mostert B, Bolt-de Vries J, Peeters D, de Jongh FE, Stouthard JM, Dirix LY, van Dam PA, Van Galen A, de Weerd V: mRNA and microRNA expression profiles in circulating tumor cells and primary tumors of metastatic breast cancer patients. Clin Cancer Res. 2011, 17: 3600-3618. 10.1158/1078-0432.CCR-11-0255View ArticlePubMedGoogle Scholar
- Hannafon BN, Sebastiani P, De Las Morenas A, Lu JN, Rosenberg CL: Expression of microRNA and their gene targets are dysregulated in preinvasive breast cancer. Breast Cancer Res. 2011, 13: R24- 10.1186/bcr2839PubMed CentralView ArticlePubMedGoogle Scholar
- Lee MR, Kim JS, Kim KS: miR-124a Is Important for migratory cell fate transition during gastrulation of human embryonic stem cells. Stem Cells. 2010, 28: 1550-1559. 10.1002/stem.490View ArticlePubMedGoogle Scholar
- Cheng LC, Pastrana E, Tavazoie M, Doetsch F: miR-124 regulates adult neurogenesis in the subventricular zone stem cell niche. Nat Neurosci. 2009, 12: 399-408. 10.1038/nn.2294PubMed CentralView ArticlePubMedGoogle Scholar
- Han ZB, Yang Z, Chi Y, Zhang L, Wang Y, Ji Y, Wang J, Zhao H, Han ZC: MicroRNA-124 suppresses breast cancer cell growth and motility by targeting CD151. Cell Physiol Biochem. 2013, 31: 823-832. 10.1159/000350100View ArticlePubMedGoogle Scholar
- Wang P, Chen L, Zhang J, Chen H, Fan J, Wang K, Luo J, Chen Z, Meng Z, Liu L: Methylation-mediated silencing of the miR-124 genes facilitates pancreatic cancer progression and metastasis by targeting Rac1. Oncogene. 2013, doi: 10.1038/onc.2012.598Google Scholar
- Xia JT, Wu ZQ, Yu CP, He WL, Zheng HQ, He YL, Jian WH, Chen LZ, Zhang LJ, Li W: miR-124 inhibits cell proliferation in gastric cancer through down-regulation of SPHK1. J Pathol. 2012, 227: 470-480. 10.1002/path.4030View ArticlePubMedGoogle Scholar
- Zheng F, Liao YJ, Cai MY, Liu YH, Liu TH, Chen SP, Bian XW, Guan XY, Lin MC, Zeng YX: The putative tumour suppressor microRNA-124 modulates hepatocellular carcinoma cell aggressiveness by repressing ROCK2 and EZH2. Gut. 2012, 61: 278-289. 10.1136/gut.2011.239145View ArticlePubMedGoogle Scholar
- Shi XB, Xue L, Ma AH, Tepper CG, Gandour-Edwards R, Kung HJ, Devere White RW: Tumor suppressive miR-124 targets androgen receptor and inhibits proliferation of prostate cancer cells. Oncogene. 2013, 32: 4130-4138. 10.1038/onc.2012.425PubMed CentralView ArticlePubMedGoogle Scholar
- Lv XB, Jiao Y, Qing Y, Hu H, Cui X, Lin T, Song E, Yu F: miR-124 suppresses multiple steps of breast cancer metastasis by targeting a cohort of pro-metastatic genes in vitro. Chin J Cancer. 2011, 30: 821-830. 10.5732/cjc.011.10289PubMed CentralView ArticlePubMedGoogle Scholar
- Liang YJ, Wang QY, Zhou CX, Yin QQ, He M, Yu XT, Cao DX, Chen GQ, He JR, Zhao Q: MiR-124 targets Slug to regulate epithelial-mesenchymal transition and metastasis of breast cancer. Carcinogenesis. 2013, 34: 713-722. 10.1093/carcin/bgs383PubMed CentralView ArticlePubMedGoogle Scholar
- Xiong P, Xiao LY, Yang R, Guo Q, Zhao YQ, Li W, Sun Y: Flotillin-1 promotes cell growth and metastasis in oral squamous cell carcinoma. Neoplasma. 2013, 60: 395-405. 10.4149/neo_2013_051View ArticlePubMedGoogle Scholar
- Zhang PF, Zeng GQ, Hu R, Li C, Yi H, Li MY, Li XH, Qu JQ, Wan XX, He QY: Identification of flotillin-1 as a novel biomarker for lymph node metastasis and prognosis of lung adenocarcinoma by quantitative plasma membrane proteome analysis. J Proteomics. 2012, 77: 202-214.View ArticlePubMedGoogle Scholar
- Song L, Gong H, Lin C, Wang C, Liu L, Wu J, Li M, Li J: Flotillin-1 promotes tumor necrosis factor-alpha receptor signaling and activation of NF-kappaB in esophageal squamous cell carcinoma cells. Gastroenterology. 2012, 143: 995-1005. e1012, 10.1053/j.gastro.2012.06.033View ArticlePubMedGoogle Scholar
- Lin C, Wu Z, Lin X, Yu C, Shi T, Zeng Y, Wang X, Li J, Song L: Knockdown of FLOT1 impairs cell proliferation and tumorigenicity in breast cancer through upregulation of FOXO3a. Clin Cancer Res. 2011, 17: 3089-3099. 10.1158/1078-0432.CCR-10-3068View ArticlePubMedGoogle Scholar
- Gong H, Song L, Lin C, Liu A, Lin X, Wu J, Li M, Li J: Downregulation of miR-138 sustains NF-kappaB activation and promotes lipid raft formation in esophageal squamous cell carcinoma. Clin Cancer Res. 2013, 19: 1083-1093. 10.1158/1078-0432.CCR-12-3169View ArticlePubMedGoogle Scholar
- Iorio MV, Croce CM: microRNA involvement in human cancer. Carcinogenesis. 2012, 33: 1126-1133. 10.1093/carcin/bgs140PubMed CentralView ArticlePubMedGoogle Scholar
- Bartel DP: MicroRNAs: target recognition and regulatory functions. Cell. 2009, 136: 215-233. 10.1016/j.cell.2009.01.002PubMed CentralView ArticlePubMedGoogle Scholar
- van Kouwenhove M, Kedde M, Agami R: MicroRNA regulation by RNA-binding proteins and its implications for cancer. Nat Rev Cancer. 2011, 11: 644-656. 10.1038/nrc3107View ArticlePubMedGoogle Scholar
- Wilting SM, van Boerdonk RA, Henken FE, Meijer CJ, Diosdado B, Meijer GA, le Sage C, Agami R, Snijders PJ, Steenbergen RD: Methylation-mediated silencing and tumour suppressive function of hsa-miR-124 in cervical cancer. Mol Cancer. 2010, 9: 167-PubMed CentralView ArticlePubMedGoogle Scholar
- Furuta M, Kozaki KI, Tanaka S, Arii S, Imoto I, Inazawa J: miR-124 and miR-203 are epigenetically silenced tumor-suppressive microRNAs in hepatocellular carcinoma. Carcinogenesis. 2010, 31: 766-776. 10.1093/carcin/bgp250View ArticlePubMedGoogle Scholar
- Pierson J, Hostager B, Fan R, Vibhakar R: Regulation of cyclin dependent kinase 6 by microRNA 124 in medulloblastoma. J Neurooncol. 2008, 90: 1-7. 10.1007/s11060-008-9624-3View ArticlePubMedGoogle Scholar
- Pinto R, Pilato B, Ottini L, Lambo R, Simone G, Paradiso A, Tommasi S: Different methylation and microRNA expression pattern in male and female familial breast cancer. J Cell Physiol. 2013, 228: 1264-1269. 10.1002/jcp.24281View ArticlePubMedGoogle Scholar
- Volinia S, Croce CM: Prognostic microRNA/mRNA signature from the integrated analysis of patients with invasive breast cancer. Proc Natl Acad Sci USA. 2013, 110: 7413-7417. 10.1073/pnas.1304977110PubMed CentralView ArticlePubMedGoogle Scholar
- Chan M, Liaw CS, Ji SM, Tan HH, Wong CY, Thike AA, Tan PH, Ho GH, Lee AS: Identification of circulating MicroRNA signatures for breast cancer detection. Clin Cancer Res. 2013, 19: 4477-4487. 10.1158/1078-0432.CCR-12-3401View ArticlePubMedGoogle Scholar
- , : Comprehensive molecular portraits of human breast tumours. Nature. 2012, 490: 61-70. 10.1038/nature11412View ArticleGoogle Scholar
- Gao J, Li L, Wu M, Liu M, Xie X, Guo J, Tang H: MiR-26a inhibits proliferation and migration of breast cancer through repression of MCL-1. PLoS One. 2013, 8: e65138- 10.1371/journal.pone.0065138PubMed CentralView ArticlePubMedGoogle Scholar
- Li LS, Yuan LJ, Luo JM, Gao J, Guo JL, Xie XM: MiR-34a inhibits proliferation and migration of breast cancer through down-regulation of Bcl-2 and SIRT1. Clin Exp Med. 2013, 13: 109-117.View ArticlePubMedGoogle Scholar
- Zhao Y, Li Y, Lou G, Zhao L, Xu Z, Zhang Y, He F: MiR-137 targets estrogen-related receptor alpha and impairs the proliferative and migratory capacity of breast cancer cells. PLoS One. 2012, 7: e39102- 10.1371/journal.pone.0039102PubMed CentralView ArticlePubMedGoogle Scholar
- Rothe F, Ignatiadis M, Chaboteaux C, Haibe-Kains B, Kheddoumi N, Majjaj S, Badran B, Fayyad-Kazan H, Desmedt C, Harris AL: Global microRNA expression profiling identifies MiR-210 associated with tumor proliferation, invasion and poor clinical outcome in breast cancer. PLoS One. 2011, 6: e20980- 10.1371/journal.pone.0020980PubMed CentralView ArticlePubMedGoogle Scholar
- Cremona ML, Matthies HJG, Pau K, Bowton E, Speed N, Lute BJ, Anderson M, Sen N, Robertson SD, Vaughan RA: Flotillin-1 is essential for PKC-triggered endocytosis and membrane microdomain localization of DAT (vol 14, pg469, 2011). Nat Neurosci. 2011, 14: 1617-1617.View ArticleGoogle Scholar
- Singletary SE, Allred C, Ashley P, Bassett LW, Berry D, Bland KI, Borgen PI, Clark GM, Edge SB, Hayes DF: Staging system for breast cancer: revisions for the 6th edition of the AJCC cancer staging manual. Surg Clin North Am. 2003, 83: 803-819. 10.1016/S0039-6109(03)00034-3View ArticlePubMedGoogle Scholar
- Li L, Xie X, Luo J, Liu M, Xi S, Guo J, Kong Y, Wu M, Gao J, Xie Z: Targeted expression of miR-34a using the T-VISA system suppresses breast cancer cell growth and invasion. Mol Ther. 2012, 20: 2326-2334. 10.1038/mt.2012.201PubMed CentralView ArticlePubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.